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Andrew J. Lucke, and David P. Fairlie*[a]
Cyclic peptides and macrocycles have the potential to be
membrane permeable and orally bioavailable, despite often
not complying with the “rule of five” used in medicinal chemis-
try to guide the discovery of oral drugs. Here we compare sol-
vent-dependent three-dimensional structures of three cyclic
hexapeptides containing d-amino acids, prolines, and intramo-
lecular hydrogen bonds. Conformational rigidity rather than
flexibility resulted in higher membrane permeability, metabolic
stability and oral bioavailability, consistent with less polar sur-
face exposure to solvent and a reduced entropy penalty for
transition between polar and nonpolar environments.
Peptides are attracting renewed
interest as pharmaceuticals[1] de-
spite their key constraints (high
polarity, metabolic instability,
low membrane permeability,
negligible oral bioavailability),
which compromise delivery.[2]
The immunosuppressant drug
cyclosporine A (CsA)[3] is an un-
usual peptide in that it is 20–
30% orally bioavailable, despite
violating the “rule of five” and
related parameters[4] associated
with oral absorption of small-
molecule drugs. This 11-residue
cyclic peptide has seven N-Me
amides and four NH protons in-
tramolecularly hydrogen bonded, and is flexible in solution.[5] It
has therefore been speculated that flexibility is important for
passive membrane permeability and oral absorption of pep-
tides,[6] by exposing the polar surface area maximally to water
for solubility but minimally to lipids (by forming intramolecular
hydrogen bonds) for passage through hydrophobic mem-
branes (Scheme 1). Here we compare three analogous cyclic
hexapeptides (1–3) that vary in the number of rigidifying pro-
lines, for differences in three-dimensional structure, conforma-
tional flexibility, physicochemical properties, membrane perme-
ability, metabolic stability and oral bioavailability.
Cyclic peptide 1 was synthesized by standard SPPS and cycli-
zation in solution; 2 and 3 were synthesized on resin[7a] by se-
lective N-methylation (see the Supporting Information). They
were chosen because conformational flexibility has been pro-
posed to be important for membrane permeability[6a,7] and oral
bioavailability:[6a,7a] 2, cyclo-[Leu-d-Leu(N-Me)-Leu(N-Me)-Leu-d-
Pro-Tyr(N-Me)] was >20% orally bioavailable in rats.[7a] We
aimed to increase flexibility by replacing d-Pro with d-Leu (1)
and to decrease flexibility by replacing d-Leu with d-Pro (3).
The circular dichroism (CD) spectra for 1–3 in aqueous media
were compared against that for CsA (Figure 1), with increasing
concentrations of sodium dodecyl sulfate (SDS, 0–10 mm) to
simulate an aqueous–lipid environment. CsA and 1 clearly had
different structures in water than in >2 mm SDS, as shown by
a shift in the molar ellipticity minimum to lower wavelength
(Figure 1). Neither 2 nor 3 showed a significant change over 0–
10 mm SDS. Furthermore, 1–3 displayed similar spectra over 3–
10 mm SDS, consistent with their having similar structures.
Thus, although CsA and 1 changed structure between aqueous
and water–lipid environments, 2 and 3 remained unchanged.
To investigate these structural differences for 1–3, we com-
pared their 1H NMR spectra in nonpolar and polar solvents.
Amide coupling constants (3JNHHa) for Leu1–Leu4 of 1–3 varied
by 0–0.5 Hz between solvents (CDCl3, [D6]DMSO, [D6]DMSO/
25%H2O, CD3CN/40%H2O), with the order 1>2>3 (Table 1).
The temperature coefficients (Dd/T) for Leu1–Leu4 NH chemi-
cal shifts in CDCl3 and [D6]DMSO were not especially revealing
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Scheme 1. Cyclic peptide 1 and possible conformational changes during transition from a water to membrane to
water environment.
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(Table 1). However, amide NH exchange for Leu1–Leu4 in 1–3
was slow (t1/2>700 min) in CDCl3, consistent with both NHs
being hydrogen bonded in this nonpolar solvent. In [D6]DMSO,
slow H–D exchange for 2 and 3 supports Leu1–Leu4 being hy-
drogen bonded, whereas rapid H–D exchange (<60 min) for
1 suggests no hydrogen bonds (Table 1). Together, these NMR
data predict an order of flexibility 1>2>3.
Three-dimensional structures were determined for 1–3 in
CDCl3 and [D6]DMSO (Figure 2) from distance and H-bond re-
straints derived from NOEs and H–D exchange rates (Support-
ing Information). The structures were &&calculated “deter-
mined” (also please confirm you were using 23-year-old software
[8])&& in XPLOR-NIH[8] by using a dynamic simulated anneal-
ing protocol in a geometric force field. In CDCl3, the structures
calculated for 1–3 (39, 52 and 19 distance restraints, respec-
tively) formed two Leu1–Leu4 intramolecular hydrogen bonds,
with no distance (0.2 ) or angle (28) violations (Figure 2A).
Each structure consisted of anti-parallel b-sheets connected by
type 1 b-turns at each end, thus facilitating intramolecular hy-
drogen bonding. In [D6]DMSO, the structures of 2 and 3 (51
and 18 distance restraints, respectively; Figure 2B) superim-
posed well on the structures in CDCl3, with the same two hy-
drogen bonds between Leu1 and Leu4 (no distance or angle
violations). This correlates well with the slow H-D exchange
rates in CDCl3 and [D6]DMSO for 2 and 3. In contrast, the struc-
ture of 1 calculated in [D6]DMSO from 46 distance restraints
did not form any hydrogen bonds and did not superimpose
well on the other structures (Figure 2). Although forming the
b-sheet structure in CDCl3, in [D6]DMSO 1 formed a ring-
shaped structure with N-methyl groups and carbonyls projec-
ting perpendicular to the plane of the ring, and there was no
transannular hydrogen bond.
A comparison of the Ramachandran plots (Figure 3A; phi
and psi angles for Leu1 (triangles) or Leu4 (circles)) for the 10
lowest-energy structures of 1–3 in a nonpolar (CDCl3, red) or
polar ([D6]DMSO, blue) solvent is instructive: the structures for
1–3 were well defined in CDCl3, more dispersed in [D6]DMSO,
and the order of flexibility was 1>2>3. To analyse these
structural differences in more detail, the variation between 1–3
in the angle aCO···H···N that defines the two hydrogen bonds
was examined for each solvent (Figure 3B): 118.2–176.78 for 2
and 124.5–1658 for 3 in both CDCl3 and [D6]DMSO; 144.9–
171.08 for 1 in CDCl3 but highly variable (80–1758) in
[D6]DMSO. Finally, the N··OC versus NH···O distances were also
plotted for the two Leu1–Leu4 hydrogen bonds in the ten
lowest-energy structures for 1–3 in CDCl3 versus [D6]DMSO
(Figure 3C). The distances for NH···O and N···OC that define hy-
drogen bonds are typically 1.8–2.5 and 2.8–3.5 2, respective-
ly.[9] The plots shows such distances, but they are much less
well-defined for 1 than for 2 and 3 (particularly in [D6]DMSO),
consistent with a greater flexibility of 1. In summary, the results
agree with the observations for H–D exchange, 3JNHHa and low
Dd/T (Table 1) and structure calculations (Figure 2), thus
strongly indicating the order of conformational flexibility as
1>2>3 in CDCl3 and [D6]DMSO.
Although 1–3 were not sufficiently soluble in water to
permit NMR studies, the CD spectra (Figure 1) hint at the same
order of flexibility in water, so we conducted molecular dynam-
ics simulations (10 ns, 298 K) for 1–3 in a water box model (Fig-
ure 4A): the backbone RMSD variations also gave the order
Figure 1. Circular dichroism spectra of CsA and 1–3 at 100 mm in 10 mm
phosphate buffer (pH 7.4, 5% MeCN) with different concentrations of SDS
(c : 0 mm, c : 1 mm, c : 2 mm, c : 3 mm, c : 4 mm, c : 5 mm,
c : 10 mm).
Table 1. Comparison of NMR parameters for amides in 1–3.
Leu1/
Leu4
Solvent 1 2 3
3JNHHa [Hz]
D 3JNHHa
CDCl3 9.4/9.5 9.7/9.1 9.2/9.3
[D6]DMSO 9.1/9.0 9.5/8.9 9.2/9.2
[D6]DMSO/
25% H2O
9.3/9.1 9.5/8.9 9.2/9.4
CD3CN/
40% H2O
9.4/9.4 9.7/9.1 9.2/9.4
0.3/0.5 0.2/0.2 0/0.2
Dd/T
[ppbK1]
CDCl3 1.8/2.1 1.4/1.0 1.6/1.3
[D6]DMSO 3.2/3.2 1.3/0.3 3.2/3.2
t1/2 [min] CDCl3 760/2.510
3 4.1103/6.5103 6.4103/8.2103
[D6]DMSO 55/24 4.110
3/5.4103 1.3105/1.3105
Figure 2. Ten NMR-derived lowest-energy backbone structures of 1–3 in
nonpolar (CDCl3) or polar ([D6]DMSO) solvents, showing prolines, N-Me and
Leu1···Leu4 intramolecular hydrogen bonds (dashed lines).
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1>2>3 for flexibility in water. Finally, 2 was energy
minimized in simulated-water and chloroform envi-
ronments: there was no structural difference in the
peptide backbone (Figure 4B). Thus, although 2 and
3 adopt the same rigid backbone conformations in
polar and nonpolar solvents (Figures 2–5), 1 is much
more flexible and adopts different, solvent-depen-
dent conformations, as depicted in Scheme 1.
Having established the relative conformational flex-
ibilities for 1–3, we sought to investigate how these
differences affect membrane permeability, liver mi-
crosomal stability and oral absorption. The passive
membrane permeabilities (Papp) obtained from paral-
lel artificial membrane permeability assay (PAMPA)
data (Table 2) had the order 1<2<3 (the more rigid
3 had the lowest calculated polar component of sur-
face area in 3D structures (FISA) and was the most
permeable). These findings are in accordance with
other studies that have reported that strong intramo-
lecular hydrogen bonds facilitate passive permeability
for cyclic hexapeptides of this class.[7, 10] All three pep-
tides were stable in plasma, and an in vitro metabo-
lism assay with liver microsomes revealed an inverse
relationship between clearance rate &&(CLint) Is this
usually an abbreviation for “intrinsic clearance? (and is
this the same as “microsomal stability” at the begin-
ning of the paragraph?)&& and rigidity: the most
rigid peptide (3) displayed the lowest clearance rate,
and the most flexible peptide (1) showed the highest
(Table 2). This metabolic stability in cells correlates with PAMPA
permeability (most rigid and metabolically stable peptide has
the highest permeability).
To investigate whether flexibility or rigidity is preferred for
oral absorption in these hexapeptides, 1–3 were administered
by oral gavage (10 mgkg1 in olive oil) to male Wistar rats, and
blood samples were removed periodically. CsA (10 mgkg1 in
olive oil) was used as a control ; as these compounds are not
soluble in water, intravenous doses were in DMSO at
1 mgkg1. There were clear &&qualitative “quantitative”?&&
differences between the pharmacokinetic profiles of the com-
pounds (Figure 5). The plasma oral concentration curves show
more rapid absorption of 2 and 3 (maximum plasma concen-
Figure 3. Angle and distance data from the ten lowest-energy NMR-derived solution
structures for 1, 2 and 3. A) Phi/psi angle plot, B) Angle aNH···O for hydrogen bonds
(shaded areas are allowed angles for H-bonds), C) Plot of HN···OC distance against N···O=
C distance, involving Leu1 (CDCl3 D, [D6]DMSO D) and Leu4 (CDCl3 0, [D6]DMSO 0).
Figure 4. Molecular modelling of 1–3. A) Molecular dynamics simulations of
NMR solution structures (RMSD variations of backbones) of 1–3 over 10 ns
in a water box model at 300 K: backbone flexibility 1>2>3 (for 100 ns sim-
ulations see the Supporting Information). B) Energy minimization of 2 in a di-
electric medium simulating water and in chloroform (showing no structural
difference).
Table 2. Hydrophilic surface area, PAMPA permeability and in vitro meta-
bolic stability of 1–3.
1 2 3
FISA [2][a] 127.5 122.5 110.4
Papp [10
6 cms1][b] <0.1 1.0 (0.5) 6.8 (2.1)
CLint [mLmin
1mg1][c] 19.1 (0.4) 14.0 (1.8) 7.3 (1.6)
plasma t1/2 [min]
[d] >60 >60 >60
[a]&&Ave “Average”? (please define)&& hydrophilic area of total sol-
vent-accessible surface area of NMR solution structures in Figure 3 calcu-
lated in Maestro (Schrçdinger). [b] PAMPA vs. propanol Paap 2.1
105 cms1. [c] Rat liver microsomal clearance. [d] Rat plasma half-life.
ChemBioChem 0000, 00, 0 – 0 www.chembiochem.org  0000 Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim3
These are not the final page numbers! 
Communications
1 1
2 2
3 3
4 4
5 5
6 6
7 7
8 8
9 9
10 10
11 11
12 12
13 13
14 14
15 15
16 16
17 17
18 18
19 19
20 20
21 21
22 22
23 23
24 24
25 25
26 26
27 27
28 28
29 29
30 30
31 31
32 32
33 33
34 34
35 35
36 36
37 37
38 38
39 39
40 40
41 41
42 42
43 43
44 44
45 45
46 46
47 47
48 48
49 49
50 50
51 51
52 52
53 53
54 54
55 55
56 56
57 57
trations at 1–3 h) than for 1 and CsA (maxima at 4–6 h). The
fast absorption of 2 and 3 hints at the involvement of active
transport, whereas the more flexible 1 and CsA can potentially
vary their degree of polar surface exposure, thereby permitting
greater partitioning to other compartments than for 2 and 3.
This appears to be supported by different volumes of distribu-
tion (CsA: 4.53.0 LKg1; 1: 1.60.5 LKg1; 2 : 0.7(
0.6) LKg1; 3 : 0.9(0.05) LKg1), with the more rigid 2 and 3
being more evenly distributed in the body water than the
more flexible 1 and CsA, which might undergo more compart-
mental partitioning. The locked conformations of 2 and 3
might favour membrane permeability, or perhaps there is
a transporter that shuttles peptides into epithelial cells of the
intestinal lumen. Peptide transporters are highly expressed in
the upper intestine, some with specificity for peptides with ty-
rosine side chains and thus improved oral bioavailability.[11]
Rigid cyclic peptides like 2 and 3 retain the turn conformation
that might be better recognized[10] by a transporter protein
than the more flexible 1. Oral bioavailabilities were 183%
(1), 164% (2), 307% (3), and 213% (CsA), thus suggest-
ing that rigidity leads to greater oral bioavailability.
In conclusion, we recently showed that protection of polar
patches on cyclic peptide surfaces from water increased intes-
tinal absorption after oral delivery to rats.[12] &&Here = the
present publication or your ‘recent’ publication? Please clarify&
& we compared compounds (1, 2 and 3) with identical H-
bond donors (HBD=3), H-bond acceptors (HBA=13) and &
&tPSA please define&& (tPSA, 159.7), and found that reduc-
tions in molecular weight (785>755>725), rotatable bonds
(12>10>8), and hydrophilic surface area (FISA 127.5>122.5>
110.4 2) all favour oral bioavailability. Successive incorporation
into 1 of one proline (2), then two (3), was expected to rigidify
the cyclic peptide. CD and NMR spectroscopy and molecular
dynamics simulations were used to analyse their structures in
polar and nonpolar solvents. The combination plots of Rama-
chandran phi/psi angles, NH···OC angles, and NH···OC versus
N···OC distances (Figure 4) proved to be a very sensitive mea-
sure of conformational flexibility/rigidity—more effective than
simply inspecting the overall ensemble of NMR-derived struc-
ture calculations. It was found that replacing two N-Me-d-leu-
cines (1) with two d-prolines (3) did indeed significantly rigidify
the cyclic peptide backbone, substantially reduce polar surface
area, significantly increase membrane permeability and liver
microsome stability, and qualitatively increase oral bioavailabil-
ity in rats. Conventional predictors of oral bioavailability for
small organic molecules (e.g. , calculated logP, tPSA, permeabil-
ity assays, in vitro metabolic stability, etc.) did not seem to cor-
rectly predict oral bioavailability for these peptides, with CsA
and 1–3 all violating rule-of-five and associated parameters.[4]
In vitro passive permeability and liver microsomal stability
(Table 2) did not predict good pharmacokinetic profiles, but in
vivo measurements showed appreciable oral absorption into
plasma and stability in the circulation. This study has suggest-
ed that both rigid and flexible compounds can have some oral
bioavailability, perhaps for different pharmacokinetic reasons (
&&Figure 6A, B vs. C, D Figure 5? (but this is not labelled “A”–
“D”)&&). Overall the results are consistent with oral pharma-
cokinetics and bioavailability being enhanced by structural ri-
gidity, as recently reported for cyclic heptapeptides,[12] rather
than by a capacity for the conformational transition highlight-
ed by Scheme 1.
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&& –&&
Flexibility versus Rigidity for Orally
Bioavailable Cyclic Hexapeptides
Three similar cyclic peptides with vary-
ing flexibility were compared for mem-
brane permeability, oral bioavailability
and metabolic stability. We show that
more-rigid structures performed better,
possibly as a result of the reduced ex-
posure of polar surfaces and lower en-
tropy penalty associated with crossing
a membrane.
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